HSV-2 is one of the most common sexually transmitted infections in the world. Globally, about 520 million people between the ages of 15 and 49 are living with it, which works out to roughly 13% of that age group. In the United States, about 12% of people aged 14 to 49 have HSV-2, and around 1 million new infections occur each year.
Prevalence in the United States
National survey data from 2015 to 2016 found that 11.9% of Americans aged 14 to 49 tested positive for HSV-2 antibodies. That translates to roughly 1 in 8 people in that age range. More recent modeling from 2020 puts the number closer to 1 in 5 adults, or about 50 million people, partly because prevalence climbs with age and those estimates include people over 49.
The difference between those two figures matters. The 12% number comes from blood testing a representative sample of 14- to 49-year-olds. The 50-million figure accounts for the full adult population, including older age groups where rates are higher. Either way, HSV-2 is far more widespread than most people realize.
How Rates Change With Age
HSV-2 prevalence rises steadily the older you get, which makes sense for a lifelong infection that accumulates over years of sexual activity. Among U.S. teens aged 14 to 19, only about 0.8% test positive. That jumps to 7.6% for people in their 20s, 13.3% for those in their 30s, and 21.2% for those in their 40s. By middle age, roughly 1 in 5 people carry the virus.
Women Are Affected More Often
HSV-2 infects women nearly twice as often as men. The reason is biological: the virus transmits more efficiently from men to women during sex than the other way around. Studies of couples where one partner has symptomatic genital HSV-2 show annual transmission rates of 11 to 17% when the man is the infected partner, compared to 3 to 4% when the woman is the infected partner. The mucosal tissue of the vagina and cervix is more susceptible to viral entry than penile skin.
Racial Disparities in the U.S.
CDC survey data from 2005 to 2008 revealed stark differences by race and ethnicity. HSV-2 prevalence was 39.2% among non-Hispanic Black Americans, compared to 12.3% among non-Hispanic white Americans and 10.1% among Mexican Americans. That gap persisted even when researchers controlled for the number of sexual partners. Among people with two to four lifetime partners, prevalence was 34.3% for Black Americans versus 9.1% for white Americans.
These disparities likely reflect differences in sexual network patterns and access to healthcare rather than individual behavior. When a virus is already more common within a community, each new sexual contact carries a higher probability of exposure, creating a self-reinforcing cycle.
Most People Don’t Know They Have It
Perhaps the most striking number: about 81% of people with HSV-2 have never been diagnosed. Many infections produce mild symptoms that get mistaken for something else, like ingrown hairs, yeast infections, or general skin irritation. Some people never have noticeable symptoms at all. This means the vast majority of transmission comes from people who don’t know they’re infected.
Routine STI panels typically don’t include herpes testing. The CDC does not recommend universal HSV-2 screening for people without symptoms, in part because of concerns about test accuracy and the psychological burden of diagnosis for an infection that may never cause problems. So even people who get tested regularly for other STIs may never have been checked for herpes specifically.
Blood Tests Aren’t Perfect
HSV-2 is detected through blood tests that look for antibodies, but not all tests perform equally well. The most commonly used lab platforms have high specificity (over 98%) and sensitivity (over 97%) for HSV-2, meaning they correctly identify both positive and negative results in most cases. However, one widely used platform (DiaSorin) has notably lower accuracy. At the 12% prevalence typical in the U.S., nearly 1 in 3 positive results from that platform would be false positives.
The problem is especially pronounced with “low positive” results, where the test index value falls just above the cutoff. About 21% of low-positive HSV-2 results on the less accurate platform turn out to be wrong. If you receive a low-positive result, confirmatory testing with a different method is worth pursuing before drawing conclusions.
Global Picture
The 13% global prevalence masks significant regional variation. Sub-Saharan Africa has the highest rates, while parts of East Asia and Western Europe tend to have lower prevalence. Women bear a disproportionate burden everywhere. The WHO estimates that HSV-2 also increases the risk of acquiring HIV by roughly threefold, making it a significant public health concern in regions where both infections are common.
New infections continue at a steady pace worldwide. In the U.S. alone, projections suggest over 600,000 new infections per year will continue for decades, potentially adding 18 million cases by 2050. Because there is no cure and no vaccine, prevalence only moves in one direction over a person’s lifetime: the virus stays once acquired.
Putting the Numbers in Perspective
HSV-2 is common enough that if you’re in a room with eight adults over 40, statistically one or two of them carry the virus. It’s less common than oral herpes (HSV-1), which affects nearly half of Americans in the same age range, but far more common than most people assume. The combination of high prevalence, low diagnosis rates, and infrequent testing means that herpes circulates largely invisibly through the population. For most people who have it, the infection is a manageable, often unnoticeable part of life rather than a serious medical problem.